Monday, Jul 16, 2018
engineered enzymes for better healthcare

 

Maple Syrup Urine Disease (MSUD) is a disorder due to a deficiency of an enzyme affecting the metabolism of branched-chain amino acids. The MSUD incidence is on average 1 in 200,000 newborns in the world (1 in 125,000 in Ireland). Newborns with MSUD typically appear normal, but by the first week of life can present with feeding difficulties, lethargy and failure to thrive. MSUD in newborns can lead to progressive neurological problems, acidosis, seizures and sudden apnoea that can rapidly lead to coma and death. Early detection and strict dietary treatment can prevent severe mental retardation and death.

Product Info

 

amino acid disorders productDisorders of Amino Acid Metabolism

PKU        Phenylketonuria

MSUD     Maple Syrup Urine Disease

HCY        Homocystinuria

TYR-I      Tyrosinaemia Type-I

 

Language Selection

Search

Latest News

Newborn Screening - First Steps into the marketplace
Irish technology to enable metabolic disorder screening among newborns in the developing world and remote locations... Read full article on the web Technology…

Read more...

Screen your baby’s health
Enzolve Technologies recently launched a novel newborn screening test for Phenylketonuria (PKU), an inherited metabolic disorder that results in severe mental…

Read more...

UCD campus company to begin production of newborn screening kits for international markets
Enzolve Technologies has recently secured substantial investment from Enterprise Ireland to allow them to begin immediate production of diagnostic screening kits…

Read more...